Bullish chart signals and looks like good outlook. Recent earnings has made the IV way more attractive for entry.
Look for $65 target in next month and then back up to $75.
Trade with caution. There is a 6% short interest on this. Not considered high, but not nothing.
CRSPR technology is the future. With treatments already being implemented such as for Duchenne's Muscular Dystrophy, this technology is going to keep making strides.
CRSPR is a gene-editing tool used by scientists to engineer animal models and create potential treatments for genetic disorders.